NCT07447102

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

A Phase II Clinical Study to Evaluate the Efficacy and Safety of BC006 in Patients With Idiopathic Pulmonary Fibrosis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Dragonboat Biopharmaceutical Company Limited · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.

Conditions

• Idiopathic Pulmonary Fibrosis (IPF)

Interventions

Type	Name	Description
DRUG	BC006	A 1.0 mg/kg or 0.3 mg/kg IV infusion of BC006 based on the patients weight will be administered Q2W to Week 24.
DRUG	Placebo	lacebo matching BC006 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.

Timeline

• Start date: 2026-04-01
• Primary completion: 2029-04-01
• Completion: 2029-04-01
• First posted: 2026-03-03
• Last updated: 2026-03-03